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Abstract  
One important challenge for regenerative medicine is to produce a clinically relevant number of cells 
with consistent tissue-forming potential. Isolation and expansion of cells from skeletal tissues results 
in a heterogeneous population of cells with variable regenerative potential. More consistent tissue 
formation could be achieved by identification and selection of potent progenitors based on cell surface 
molecules. In this study, we assessed the expression of stage-specific embryonic antigen-4 (SSEA-
4), a classic marker of undifferentiated stem cells, and other surface markers in human articular 
chondrocytes (hAC), osteoblasts (hOB), and bone marrow-derived mesenchymal stromal cells 
(bmMSCs) and characterized their differentiation potential. Further, we sorted SSEA-4 expressing 
hACs and followed their potential to proliferate and to form cartilage in vitro. Cells isolated from 
cartilage and bone exhibited remarkably heterogeneous SSEA-4 expression profiles in expansion 
cultures. SSEA-4 expression levels increased up to ~5 population doublings but decreased following 
further expansion and differentiation cultures; levels were not related to the proliferation state of the 
cells. Although SSEA-4-sorted chondrocytes showed slightly better chondrogenic potential than their 
SSEA-4-negative counterparts, differences were insufficient to establish a link between SSEA-4 
expression and chondrogenic potential. SSEA-4 levels in bmMSCs also did not correlate to the cells’ 
chondrogenic and osteogenic potential in vitro. SSEA-4 is clearly expressed by subpopulations of 
proliferating somatic cells with a MSC-like phenotype. However, the predictive value of SSEA-4 as a 
specific marker of superior differentiation capacity in progenitor cell populations from adult human 
tissue and even its usefulness as a stem cell marker appears questionable. 
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Introduction 
Treatment options for musculoskeletal disorders are limited and new therapeutic approaches are 
being investigated including the repair of lost or damaged cartilage and bone with tissue engineering 
and regenerative medicine (TE/RM) techniques. One important challenge in the area of TE/RM is to 
produce a clinically relevant number of cells with consistent tissue-forming potential. However, 
isolating and culturing cells from various tissue sources, such as bone marrow, cartilage, and bone, 
results in a heterogeneous cell population with variable amounts of progenitors (1-2), and therefore 
heterogeneous and often unpredictable tissue formation (3-4).  
Identification and isolation of specific cells with regenerative capacity could lead to more 
consistent tissue formation (5-7). Cell surface markers can be used, to simultaneously characterize 
and sort cells using magnetic or fluorescent antibodies, resulting in populations with specific surface 
characteristics. A wide range of cell surface antigens have been studied on the various progenitor cell 
types (8), with the most frequently reported negative and positive markers of mesenchymal stromal 
cells (MSC) being CD14, CD34, CD45 and CD44, CD90, CD73, CD105, respectively (9). Given that 
mature stromal cells, including articular chondrocytes, lose their differentiated state during in vitro 
expansion and adopt a mesenchymal-like phenotype (10-12), it is not surprising that propagated 
chondrocytes and osteoblast express a similar range of surface markers to MSCs (13-15). However, 
there are conflicting reports about the antigenic characteristics of mesenchymal progenitor cells and 
reliable markers of progenitor populations have yet to be identified (1, 16).  
Stage-specific embryonic antigen-4 (SSEA-4) is one cell surface molecule with potential use 
for the identification and sorting of progenitor cells for musculoskeletal regeneration. The SSEA-4 
epitope has been identified as a globo-series glycosphingolipid (GSL) with a terminal sialic acid 
(monosialyl-Gb5) (17). It is commonly used to characterize undifferentiated human embryonic stem 
cells (18). Yet, SSEA-4 is also expressed by human MSCs isolated from a variety of sources including 
placenta (19), umbilical cord blood (20), amniotic fluid (21), bone marrow (bm)(22), dermis (23) and 
ligament (24). By using both SSEA-4 expression and plastic adherence, Gang et al. were able to 
isolate cells with multipotent differentiation potential from human bone marrow aspirates (22). 
However, bmMSCs started to express SSEA-4 levels at a remarkably wide intensity range after 
expansion, pointing to increasing heterogeneity in originally SSEA-4 positive cells. This raises the 
question if changes in SSEA-4 levels of cells are also indicative of shifts in their differentiation 
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potential. Moreover, SSEA-4 expression by in vitro cultured, dedifferentiated stromal cells important 
for musculoskeletal regeneration, including human articular chondrocytes (hAC) and osteoblasts 
(hOB), has not been investigated.  
Therefore, we have characterized the expression profiles of SSEA-4 and other cell surface 
markers on human cell populations relevant for the regeneration of skeletal tissues, at different stages 
of cultivation. In particular, we have compared SSEA-4 levels on propagated hAC, hOB and bmMSCs 
with the differentiation potential of these cells. Further, we have sorted SSEA4 expressing hAC and 
followed their SSEA-4 expression during further expansion and also their potential to form cartilage in 
vitro. Finally, we have investigated the potential functional relevance of SSEA-4 expression in hAC 
and bmMSCs.  
 
Materials and Methods 
Cell isolation and expansion 
Articular cartilage of non-osteoarthritic origin (non-OA; donors: 2 male + 2 female, age 54-77 years) 
was collected with institutional ethics approval from consenting patients undergoing limb amputations. 
Osteoarthritic (OA) cartilage (donors: 2 male + 4 female, age 59-78 years) from visually normal 
regions (International Cartilage Repair Society anatomical grade 0-1 (25)) and trabecular bone 
samples (3 female donors, age 59-82 years) were obtained from consenting patients during joint 
replacement surgery.  
Chondrocytes were isolated either from full-thickness cartilage or the superficial and the 
middle/deep tissue layers separately, as described previously (26). Chondrocytes were propagated 
on tissue culture plastic (3,000 cells/cm2) in chondrocyte basal medium (low-D-glucose Dulbecco’s 
Modified Eagle Medium with 4 mM L-alanyl-L-glutamine, 1 mM sodium pyruvate, 10 mM N-(2-
hydroxyethyl)piperazine-N′-(2-ethanesulfonic acid) (HEPES), 0.1 mM non-essential amino acids, 50 
U/mL penicillin / 50 μg/mL streptomycin (Pen/Strep) (all from Invitrogen, Carlsbad, CA), 0.1 mM L-
ascorbic acid 2-phosphate and 0.4 mM L-proline (both Sigma Aldrich, St. Louis, MO) supplemented 
with 10% fetal bovine serum (FBS) (Hyclone, Logan, UT).  
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Human primary osteoblasts were isolated by outgrowth from minced and washed bone 
specimens(27), cultured in Minimum Essential Medium Alpha (α-MEM) (Invitrogen) with Pen/Strep 
and 10% FBS, and subsequently plated at 2,000 cells/cm2. 
BmMSCs were either purchased from the laboratory of Dr. Darwin Prockop, Texas A&M 
University (donors #1-3) or isolated from bone marrow aspirates obtained under appropriate ethical 
approval from the iliac crest of consenting patients undergoing spinal fusion surgery (donors #4-6), 
(gender and age of bmMSC donors in Table 1). Total bone marrow cells were plated in α-MEM 
supplemented with 10% FBS, Pen/Strep and 1 ng/mL Fibroblast Growth Factor 2 (FGF-2) (Millipore, 
Billerica, MA). BmMSCs were initially seeded at 100 cells/cm2, subsequently plated at 1,000 
cells/cm2, and used between passages 3-4.  
All cells were maintained at 37˚C in a humidified 5% CO2/95% air CO2 incubator with medium 
refreshed twice per week. Cells were passaged when subconfluent with 0.25% trypsin with 1 mM 
ethylenediamine tetraacetic acid (trypsin/EDTA) (Invitrogen) at 37˚C for 5 min. Cells were counted by 
trypan blue (Invitrogen) exclusion in a haemocytometer. Cell population doublings were calculated 
using the logarithm (base 2) of the quotient between final and initial cell numbers.  
 
Flow cytometry analysis and fluorescence-activated cell sorting (FACS) 
Harvested cells were incubated for 30 min in phosphate buffered saline with 3% m/v bovine serum 
albumin (Sigma) (3% BSA/PBS ) and one of the following antibodies: CD14 (phycoerythrin (PE)-
conjugated, 1:20, UCHM-1, Millipore), CD45 (1:20, H5A5, Developmental Studies Hybridoma Bank 
(DSHB), Iowa City, IA), CD44 (1:20, H4C4, DSHB), CD90 (fluorescein isothiocyanate (FITC)-
conjugated, 1:20, F15-42-1, Millipore), CD105 (1:40, P4A4, DSHB), SSEA-1 (1:40, MC-480, DSHB), 
SSEA-3 (1:40, MC-631, DSHB), SSEA-4 (1:80, MC-813-70, DSHB) or IgG isotype control (1:50, 
Invitrogen). Cells were washed twice with cold PBS and samples with unconjugated primary 
antibodies were incubated for 45 min in 3% BSA/PBS containing either FITC-labeled goat anti-mouse 
IgG antibody (1:80, CALTAG, Burlingame, CA) or DyLight™649-conjugated goat anti-rat IgG antibody 
(1:40, Jackson ImmunoResearch, West Grove, PA, USA). Finally, samples were washed with cold 
PBS and resuspended in 3% BSA/PBS.  
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For cell cycle analysis, harvested cells were fixed with ice-cold 70% v/v ethanol for 15 min 
and incubated in 3% BSA/PBS with 0.1 mg/mL RNase A solution (Invitrogen), 0.1% Triton X-100 and 
0.1 mg/mL propidium iodide (PI) (Invitrogen) for 45 min in the dark. 
Approximately 104 cells were analyzed on a FC500 flow cytometer (Beckman Coulter, Fullerton, CA) 
with appropriate filters for FITC, PE, PI or DyLight™649. For each cell surface antigen, histograms 
and the percentage of positive cells were determined after Overton’s method (28) with CXP software 
(Beckman Coulter).  
FACS was used to separate SSEA-4-positive from SSEA-4-negative subpopulations of 
chondrocytes. In brief, 4x106 hAC harvested at passage 2 (4 donors; mean population doublings 
(PD): 4.4 ± 1.1 standard deviation (SD)) were stained for SSEA-4-FITC and sorted on a FACS Aria IIu 
(BD Biosciences, Franklin Lakes, NJ). One third of total sorted cells with lowest or highest 
fluorescence intensity values were considered SSEA-4 negative (SSEA-4-) or SSEA-4 positive 
(SSEA-4+), respectively, and used in subsequent proliferation and differentiation experiments.  
 
Immunofluorescence analysis 
Immunofluorescence was used to determine localization of SSEA-4 in cartilage and in cell cultures. 
Formalin-fixed human cartilage specimens were dehydrated in a graded ethanol series, embedded in 
paraffin, and cut to yield ~5 µm thick cross-sections. Cells grown on chamber glass slides (BD 
Biosciences) were washed with PBS and fixed for 20 min in PBS with 4% w/v formaldehyde. Samples 
were treated with 0.025% w/v hyaluronidase (Sigma) in PBS for 20 min at 37°C and blocked with 1% 
BSA/PBS for 30 min. Selected samples received an additional treatment with either 0.2% v/v Triton X-
100 or ice-cold 100% v/v methanol for 10 min after the antigen retrieval. Samples were subsequently 
incubated with SSEA-4, SSEA-3 or IgG-matched control antibodies in 1% BSA/PBS for 45 min. 
Subsequently, AlexaFluor®488 or AlexaFluor®633 goat anti-mouse or DyLight™649 goat anti rat 
antibodies as well as 5 µg/mL 4′,6-diamidino-2-phenylindole (DAPI, Sigma) and - where required - 0.8 
U/mL phalloidin rhodamine (Invitrogen) were applied for 1h in the dark. For double staining with CD14 
or CD90, samples were treated with the specified antibodies for 30 min in the dark in a final step. 
Images were captured using a confocal laser scanning microscope (Leica, Wetzlar, Germany). 
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Cell proliferation of SSEA-4 sorted cells 
To compare proliferation capacity, SSEA-4+ and SSEA4- hAC were seeded at 2,000 cells/cm2 (2 
donors) and cultured as described under chondrocyte expansion conditions. At day 1, 4 and 7 of 
culture, cells were harvested for DNA quantification by incubation with 0.5 mg/mL proteinase K 
(Invitrogen) in a phosphate buffer (20 mM Na2HPO4, 30 mM NaH2PO4.H2O, 5 mM EDTA, pH 7.1) for 
15 min and complete digestion in 1.5 mL tubes overnight at 60°C. Population doubling times were 
calculated by dividing the cultivation period by the population doublings, which were determined 
based on the change in DNA content, as described above. 
 
Chondrogenic differentiation  
Chondrogenic potential was evaluated using either micromass pellet or alginate hydrogel cultures. 
Pellets (2x105 cells) of both chondrocytes and bmMSCs were formed by centrifugation (26). 
Chondrocytes were also encapsulated in 2% w/v sodium alginate (Pronova UP LVG, 
Novamatrix/FMC BioPolymers, Sandvika, Norway) at 107 cells/mL and cross-linked with 102 mM 
CaCl2 solution in wells (20 µL volume) of a custom-made mould. Cells were cultivated in serum-free 
high-glucose chondrocyte basal medium supplemented with 1.25 mg/mL BSA, 10-7 M 
dexamethasone, 1% v/v ITS+1 (all from Sigma), and 10 ng/mL transforming growth factor type beta 1 
(TGF-β1) (Invitrogen)) and kept under reduced (5%) oxygen tension in a ProOx C-Chamber 
(Biospherix, Redfield, NY) inside a cell culture incubator. Cultures were maintained for up to two 
weeks with media refreshed twice per week. For flow cytometry analysis, cells were released from 
alginate constructs by dissolving the hydrogel in 0.15% trypsin / 20 mM EDTA for 15 min. 
 
Quantification of glycosaminoglycans (GAG) and DNA 
The GAG content of digested cell pellets was quantified using the 1,9-dimethylmethylene blue dye 
(DMMB) assay, with absorbance at 525 nm measured in a Benchmark Plus microplate 
spectrophotometer (Bio-Rad Laboratories, Hercules, CA).(29) 
The Quant-iT™ PicoGreen® dsDNA assay (Invitrogen) was used to quantify DNA content in 
digested samples, with fluorescence (485 nm excitation, 520 nm emission) measured using a 
POLARstar OPTIMA fluorescence micro-plate reader (BMG Labtech, Offenburg, Germany).  
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Ribonucleic acid (RNA) extraction and real-time reverse transcriptase-polymerase chain reaction 
(qRT-PCR) 
To measure absolute expression levels of selected genes of interest, qRT-PCR was used. RNA was 
isolated using the PureLink™ RNA Micro Kit (Invitrogen) according to manufacturer’s instructions 
which included mechanic disruption of cell pellets with pestles, sample homogenization with a 20 
gauge needle and the removal of genomic DNA by on column treatment with DNase I (Invitrogen).  
First strand complementary DNA (cDNA) synthesis was performed using the SuperScript™ III first-
strand synthesis supermix for qRT-PCR (Invitrogen) with no more than 300 ng of total RNA in 20 μL 
reactions following the manufacturer’s protocol.  
Primers were either taken from the literature for RPL13A (30), used as published previously 
(COL1A1, COL2A1, COL10A1, ACAN and 18S rRNA) (26) or designed using Primer-BLAST (NCBI, 
Bethesda, MD) for MKI67 (5’3’ F:AATTCAGACTCCATGTGCCTGAG, 
R:CATTGTCCTCAGCCTTCTTTGG) and B2M (5’3’ F:ATGAGTATGCCTGCCGTGTGA, 
R:GGCATCTTCAAACCTCCATGATG). All PCR reactions were done in duplicates in 10 μL volumes 
in a 7900HT PCR system (Applied Biosystems, Foster City, CA). Reactions contained 1 X SYBR® 
Green PCR Master Mix (Applied Biosystems), 200 nM of each forward and reverse primers and 0.2 
μL of undiluted cDNA and started with 2 min denaturation at 95ºC followed by 40 cycles of 95ºC for 15 
s and 60ºC for 30 s. Absolute quantification using standard curves and post-amplification analysis 
were carried out as described previously (26). The cDNA copy number for each reaction was then 
calculated by direct comparison to the known standards and normalized to the geometric mean of 
copy numbers of three housekeeping genes (18S rRNA, RPL13A, B2M). Transcript levels of SSEA-4+ 
cells of each data point were further normalized to mRNA levels of the respective SSEA-4- samples. 
Transcript levels in bmMSCs after 14 days of chondrogenic differentiation were normalized to 
undifferentiated control cells from day 0. 
 
Osteogenic differentiation  
Osteogenic potential was evaluated in vitro. BmMSCs (2,500 cells/cm2) were cultured in 6-well plates 
in bmMSCs expansion medium for 2 weeks, and for an additional 4 weeks in bmMSCs expansion 
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medium (controls) or osteoblast expansion medium supplemented with 10-7 M dexamethasone, 50 
µg/mL L-ascorbic acid 2-phosphate (Sigma) and 10 mM β-glycerophosphate. 
 
Alkaline phosphatase (ALP) activity and calcium deposition assays 
After 3 weeks of osteogenic induction, alkaline phosphatase activity was measured in the media 
supernatant using a colorimetric assay. Briefly, media were changed to phenol red- and FBS-free α-
MEM for 24 h prior to measurements, then incubated for 3 hours with an equal volume of 1 mg/ml p-
nitrophenylphosphate in 0.2 M Tris buffer (Sigma), and absorbance was measured at 405 nm. 
Calcium deposition within the cell layer was measured using the Wako HRII calcium assay (Wako, 
Osaka, Japan) after 4 weeks of osteogenic induction, as described previously (27). Data were 
normalized to the values from undifferentiated controls. 
 
Statistical analysis 
Statistical analyses were performed using Minitab 15 (Minitab, State College, PA). Correlations 
between population doublings and SSEA-4-positive chondrocytes were analyzed by polynomial 
regression. To test for differences in the gene expression and pellet sizes, data from SSEA-4+ cells 
were normalized to SSEA-4-negative controls from the same donor (n=5 donors) and analyzed with a 
one sample t-test compared to the value of 1. Statistical significance in the proliferation assay (n=6, 2 
donors) and the comparison of surface markers expressions in zonal chondrocytes (n=3 donors) was 
tested by analysis of variance (ANOVA) using a general linear model, with donor considered as a 
random effect. Statistically significant differences were considered to be present at p<0.05. 
 
Results 
Transient and heterogeneous expression of SSEA-4 by hAC in vitro 
Chondrocytes in human articular cartilage stained at background levels for SSEA-4 (Fig. 1A). 
Accordingly, SSEA-4 expression was low or undetectable with flow cytometry on primary, freshly 
isolated hAC (Fig. 1B). However, SSEA-4 expressing cells were detectable by the first passage, 
levels peaked at ~5 population doublings, and decreased again beyond passage 2 (Fig 1B+D). 
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Chondrocytes from osteoarthritic (OA) and non-OA origin shared similar SSEA-4 expression profiles 
during monolayer expansion (Fig. 1D). We found no differences in surface marker expressions 
between expanded cells isolated from different zones of cartilage (Fig. 1E). There were at least two 
distinct subpopulations (high or low) of SSEA-4 expressing cells (Fig. 1B-D). In contrast, monolayer-
expanded chondrocytes homogeneously expressed high levels of the mesenchymal cell markers 
CD44, CD90 and CD105 and were negative for the hematopoietic cell markers CD14 and CD45, 
when tested with flow cytometry (Fig. 1F). Expression of the various surface markers was confirmed 
with confocal microscopy. Propagated hAC exhibited varying staining intensities for SSEA-4, while 
showing no or homogeneous staining for CD14 or CD90, respectively (Fig. 1C). There were no 
obvious phenotypic differences between SSEA-4 positive and negative cells. Interestingly, SSEA-4 
expression of chondrocytes was essentially lost following two weeks of redifferentiation in alginate 
hydrogels (Fig. 1G), whereas CD44 was still presented by the majority of cells (data not shown). 
 
Proliferation and chondrogenic potential of hAC sorted for SSEA-4 
Passage 2 chondrocytes were separated by FACS based on their SSEA-4 expression levels (Fig. 2A) 
and either further propagated in monolayer or redifferentiated in micromass pellets. Following an 
additional passage (~3 population doublings), a high number of SSEA-4+ cells had lost SSEA-4 
expression, while a subpopulation of initially SSEA-4- cells gained expression of this marker (Fig. 2B). 
Gene expression levels of the proliferation marker MKI67, which is detectable during all active phases 
of proliferation (G1, S, G2, and mitosis) (31), were comparable in SSEA-4+ and SSEA-4- cells after 
sorting (p=0.09) (Fig. 2C). SSEA-4- hAC appeared to proliferate faster initially between day 1 and 4 of 
culture on tissue culture plastic compared to the SSEA-4+ cells (p=0.02) (Fig. 2D). However, 
population doubling times were equal between the two groups between day 4 and 7 of propagation 
(p=0.7). To test if cells at different stages of the cell cycle account for the differences in SSEA-4 
expression levels, we performed a cell cycle analysis on unsorted passage 2 hAC using PI staining; 
69.9% of cells were SSEA-4-positive, 83.8% of cells in G0/1 phase and 7.9% or 7.3% in S or G2/M 
phases, respectively, suggesting that SSEA-4 expression is not simply related to the cell cycle. 
 In redifferentiation pellet culture, SSEA-4+ cells from 3 out of 5 donors tested formed pellets 
with larger diameters than SSEA-4- cells (p=0.1) (Fig. 2E). Moreover, although SSEA-4+ cells 
exhibited overall higher levels of the chondrogenic marker genes COL2A1 (p=0.001) and aggrecan 
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(p=0.03) compared to SSEA-4- cells, differences in expression levels of these genes between the two 
groups did not reach significance at any of the individual time points tested (Fig. 2F). Gene 
expression levels for COL1A1, a marker for fibroblastic, dedifferentiated chondrocytes, (p=0.4) and for 
the hypertrophy marker COL10A1 (p=0.1) were comparable in the two subpopulations. 
SSEA-4 expression in hOB during in vitro expansion 
Human osteoblasts also exhibited at least two distinct subpopulations of SSEA-4-expressing 
cells during monolayer propagation, while being negative for CD14 and CD45 and showing high, 
homogeneous expression for CD44, CD90 and CD105 (Fig. 3A,B). Similar to hAC, the SSEA-4+ 
osteoblast population decreased with continuous cell expansion (Fig. 3C,D). 
Chondrogenic and osteogenic potential of bmMSCs with varying levels of SSEA-4 expression 
To test if SSEA-4 expression levels on bone marrow-derived MSCs can be predictive of their 
differentiation potential, we determined the surface marker expression profile in bmMSCs expanded 
over 3-4 passages and cultured them under conditions to induce either chondrogenic or osteogenic 
differentiation.  
BmMSC preparations were uniformly negative for CD14 and CD45 and positive for CD44, 
CD90 and CD105 (Fig. 4A). However, flow cytometry and confocal microscopy revealed remarkable 
donor variation in SSEA-4 levels (Fig. 4B, Table 1). In general, bmMSC expression of SSEA-4 was 
heterogeneous compared to CD44, CD90 and CD105. When differentiated in micromass pellets over 
two weeks, chondrogenic markers COL2A1 and aggrecan were highly up-regulated in cells from 3 
and 1 out of 6 patients, respectively (Table 1). However, there was no correlation between mRNA 
levels for these genes, or GAG amounts per DNA in pellets, and the percentage of SSEA-4+ cells. 
Similarly, the levels of SSEA-4 expression did not correlate with ALP activities nor the amount of 
calcium deposited in bmMSCs cultured under osteogenic conditions (Table 1).  
Characterization of the SSEA-4 antigen 
To further characterize the carrier of the SSEA-4 antigen in our cell models, we tested for the 
presence of SSEA-3, which is found in the very same globo-series glycosphingolipid containing the 
SSEA-4 epitope (17). SSEA-3 expression levels were relatively low in both hAC and bmMSCs 
compared to SSEA-4, as measured with flow cytometry (Fig. 5A). BmMSCs high in SSEA-4 also 
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expressed slightly higher levels of SSEA-3. Notably, the typical staining profile with subpopulations of 
varying SSEA-4 levels was not detectable for SSEA-3. However, the staining patterns of SSEA-4 and 
SSEA-3 appeared similar on hAC grown on glass slides (Fig. 5B). Either bmMSCs nor hAC stained 
positive for the SSEA-1 antigen (data not shown). 
Treating chondrocytes as well as bmMSCs with 0.2% Triton X-100 reduced their 
immunoreactivity against SSEA-4 and left some residual, punctate perinuclear staining (Suppl. Fig. 1). 
After washing with ice-cold 100% methanol, SSEA-4 staining was completely lost in both cell types 
(data not shown).  
Discussion 
The aim of this study was to characterize the expression of the stem cell surface marker SSEA-4 in 
chondro -and osteoprogenitor cells and to test its potential to identify subsets of cells with superior 
differentiation or proliferation potential. We have shown that propagated human articular chondrocytes 
exhibit remarkably heterogeneous expression profiles for SSEA-4, which indicates the presence of at 
least two distinct cell subpopulations with either low or high levels of this surface marker. None of the 
other surface markers tested showed similar heterogeneity. The existence of chondrocyte subsets 
with distinct SSEA-4 expression is not explained by phenotypic variation of cells from different 
cartilage zones, as chondrocytes isolated from superficial and middle/deep zone of cartilage shared 
similar levels of SSEA-4. We also found that SSEA-4 was not detectable on cells of native articular 
cartilage and that it was no longer expressed in chondrocytes re-differentiated in alginate constructs. 
This is in agreement with studies that observed loss of SSEA-4 in differentiated embryonic stem cells 
(32) and MSCs (33). The increase in SSEA-4 levels during propagation could be explained by the 
presence and amplification of highly proliferative mesenchymal progenitor cell population that is 
thought to reside in cartilage (34-35). It seems more likely, however, that SSEA-4 is up-regulated 
together with an overall change from a chondrocytic to a more immature, MSC-like phenotype during 
dedifferentiation in vitro (11). Interestingly, propagated human osteoblasts display a similar SSEA-4 
expression profile to chondrocytes, suggesting that heterogenic SSEA-4 expression may be a 
common feature of in vitro expanded cells from skeletal tissues. 
SSEA-4 was only transiently expressed in expansion cultures of chondrocytes and 
osteoblasts with levels declining after prolonged monolayer cultivation. This was even more evident in 
chondrocytes sorted for SSEA-4, where a high number of SSEA-4+ cells lost their expression after 
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subsequent passage. Interestingly, some SSEA-4- cells still gained expression of this marker. The 
loss of SSEA-4 could be caused by increased replicative senescence (36) or be indicative of a rapid 
decrease in redifferentiation capacity of ex vivo expanded chondrocytes (37-38). This raises the 
question if it can be used as general marker for chondroprogenitor cells with superior differentiation 
potential. To explore this, we separated subpopulations of propagated chondrocytes with low and high 
levels of this surface marker by FACS and determined their differentiation and proliferation capacity. 
SSEA-4+ chondrocytes expressed higher levels of chondrogenic markers than SSEA-4- populations 
when redifferentiated in pellet cultures. However, it should be noted that cells devoid of this antigen 
still exhibited some degree of redifferentiation potential. There were also no clear differences in terms 
of proliferation capacity between sorted cells. Although SSEA-4- chondrocytes seemed to proliferate 
at a slightly faster rate in the first four days of culture, both groups expressed comparable amounts of 
the proliferation marker MKI67 (31). A cell cycle analyses did not reveal a link to the variation in 
SSEA-4 levels, either. Taken together, our data speak against a direct involvement or a dominant role 
of SSEA-4 in cellular processes such as proliferation, cell cycle progression or differentiation.  
A functional role for SSEA-4 in embryonic stem cells has not been identified yet. A reduction 
of SSEA-4 levels by inhibition of the GSL pathway does not affect the stem cell phenotype including 
pluripotency, but points to a role during embryonic stem cell differentiation, instead (39-40). In this 
respect, it is surprising that SSEA-4 has also been shown to be expressed on the more specialized, 
committed MSCs isolated from a number of adult human tissues (22-24). Gang et al. have even been 
able to select multipotent cells from bone marrow by employing SSEA-4 and proposed its expression 
identifies a homogeneous MSC population with superior biological properties (22). In contrast, Guillot 
et al. failed to detect SSEA-4 or other stem cell markers in adult bmMSCs (41). We found that the 
expression of SSEA-4 varies considerably between bmMSC preparations from different donors. This 
could clearly be reflective of a generally diverse repertoire of different MSC subpopulations in vivo or 
may be due to unintended, minor variations in the in vitro culture conditions that favored different 
subpopulations with varying differentiation potential (1). However, the level of SSEA-4 expression did 
not correlate with the outcome of our in vitro differentiation assays. This suggests that the predictive 
value of SSEA-4 levels in bmMSCs may be limited in respect to their chondrogenic and osteogenic 
potentials. 
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Apart from variations in the handling and the origin of MSC preparations, the nature of the 
SSEA-4 antigen could be a source of inconsistency and confusion in the literature. Brimble et al. 
reported that the SSEA-4 antigen was still present despite successful depletion of glycosphingolipids 
and SSEA-3 on their stem cell model (39). SSEA-3, another commonly used stem cell surface 
marker, recognizes a glycan moiety (Gb5) in the very same globo-series GSL containing the SSEA-4 
epitope (17). We found only relatively low levels of SSEA-3 in bmMSCs and chondrocytes, with the 
latter also lacking the heterogeneous expression profile of SSEA-4. Therefore, the majority SSEA-4 
antigen in MSCs or other cell types may not be monosialyl-Gb5. It should be noted that the SSEA-4 
antibody, clone MC-813-70, shows some weak cross-reactivity with other GSL types as well as 
glycoproteins, all carrying the NeuAcα2-3Galβ1-3GalNAc epitope (17). Indeed, the SSEA-4 epitope 
has been identified on the 34/67 laminin receptor of a murine embryonal carcinoma cell line (42). Our 
observation that Triton X-100 and ice-cold methanol abolished SSEA-4 immunoreactivity cannot 
answer the question about the carrier of the epitope, since glycolipids, as well as certain glycoproteins 
could be harbored in detergent-soluble areas on the cell surface. Further investigations into the true 
identity of the SSEA-4 carrier(s) are necessary to explain the heterogeneity of SSEA-4 on 
chondrocytes, osteoblast and bmMSC expansion cultures, which may ultimately shed some light on 
the functional importance of SSEA-4 variations in these cells. 
 
Conclusions  
Cells isolated from cartilage and bone adopt the expression of the stem cell surface marker SSEA-4 
in in vitro expansion cultures suggesting that it is expressed by subpopulations of cells with an 
immature, mesenchymal stem cell-like phenotype. Presentation of this surface antigen is remarkably 
heterogeneous and appears to be of transient nature during the cultivation period. Although SSEA-4 
positive chondrocytes show slightly better chondrogenic potential compared to chondrocytes that do 
not present this surface molecule, the differences in the differentiation capacity of the two groups are 
not pronounced enough to link SSEA-4 expression to chondrogenic progenitors with superior 
differentiation potency. In addition, SSEA-4 levels in bmMSCs seem to be unrelated to the cells’ 
chondrogenic and osteogenic potential in vitro. These data suggest that SSEA-4 is not a reliable 
marker of multipotency in bmMSCs and is not specific to dedifferentiated mature cell populations with 
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superior differentiation capacity. The fact that SSEA-4 is also expressed by more committed cell types 
also raises doubts about its usefulness as a stem cell marker in general. 
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Figure Legends 
 
Fig 1: Expression levels of SSEA-4 in human articular chondrocytes (hAC) at different stages of 
cultivation. (A) Human articular cartilage sections (non-OA source) were probed either with SSEA-4-
specific or isotype control (IgG ctrl.) antibodies (red-framed inset) and counterstained with DAPI. (B) 
Representative flow cytometry histograms of SSEA-4 plotted with an IgG control (no color) are shown 
for freshly isolated hAC and for monolayer-propagated chondrocytes after different passages (P1-3) 
and population doublings (PD) (C) HAC on glass chamber slides were probed with antibodies specific 
for SSEA-4 and either CD14 or CD90, and counterstained with DAPI. (D) Levels of SSEA-4-positive, 
monolayer-cultured hAC isolated from osteoarthritic (OA, rhombus, n= 2 donors) and non-
osteoarthritic (non-OA, triangle, n=1 donor) cartilage. (E) Surface marker levels in OA chondrocytes 
isolated from different harvest sites of articular cartilage after passage 2 (mean + standard deviation, 
n=3 donors). (F) Flow cytometry histograms of representative expression patterns of CD14, CD44, 
CD45, CD90, and CD105 plotted with controls (no color). (G) Representative flow cytometry 
histogram of SSEA-4 plotted with an IgG control (no color) for P2 chondrocytes redifferentiated two 
weeks in alginate cultures. 
 
Fig. 2: Proliferation capacity and chondrogenic potential of hAC expressing different levels of SSEA-4. 
(A) HAC (P2) were separated into SSEA-4+ and SSEA-4- subpopulations by FACS. (B) SSEA-4 
expression levels in sorted and unsorted cells after propagation for an additional passage cycle. 
Proliferation potential was compared by measuring (C) mRNA levels of MKI67 immediately after 
sorting (n=4 donors) and (D) determining population doubling times of sorted cells in monolayer 
cultures (mean+SD; n=6, 2 donors). Chondrogenic potential of SSEA-4+ and SSEA-4- was assessed 
in micromass pellet cultures by comparing (E) pellet sizes after 14 days of redifferentiation and (F) 
gene expression levels of collagen I (COL1A1), II (COL2A1), X (COL10A1) and aggrecan (ACAN) 
during pellet culture (donors A-C: non-OA, 2 male, 1 female, 54-65 y; D+E: OA, 1 male, 1 female, 
76+78 y).  
  
Fig. 3: Expression of surface markers on monolayer-expanded human osteoblasts (hOB). (A) Flow 
cytometry histograms of representative expression patterns for one donor of CD14, CD44, CD45, 
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CD90, CD105 and SSEA-4, plotted with matched IgG controls (no color). (B) Osteoblasts grown on 
glass chamber slides were probed with antibodies specific for SSEA-4 as well as either CD14 or 
CD90 and counterstained with DAPI. (C) Levels of SSEA-4-positive hOB isolated from bone explants 
cultures (P1) and propagated for various population doublings. (D) Representative histograms for 
SSEA-4 levels in osteoblasts after different passages (P2-4). 
 
Fig. 4: Expression of surface markers on bmMSC. (A) Flow cytometry histograms of representative 
expression patterns of CD14, CD44, CD45, CD90, CD105 and SSEA-4 for one donor, plotted with 
matched IgG controls (no color). (B) BmMSCs with either low or high expression of SSEA-4 (two 
representative donors) as shown by immunofluorescence (SSEA-4, CD90, DAPI) and by flow 
cytometry with percentage of SSEA-4+ cells. 
 
Fig. 5: Expression of SSEA-3 on hAC and bmMSCs in monolayer cultures. (A) Representative flow 
cytometry histograms of SSEA-3 expression profiles on hAC, and bmMSC with high or low in SSEA-4 
expression (controls: no color). (B) SSEA-3 immunofluorescence (with DAPI counterstain) on 
chondrocytes (P2) and bmMSCs (high SSEA-4 levels).  
 
Suppl. Fig. 1: SSEA-4 antigen susceptible to Triton X-100 treatment. Chondrocytes (P2) and 
bmMSCs (high SSEA-4 levels) were pre-treated with 0.2% v/v Triton X-100 or PBS before SSEA-4 
immunofluorescence staining (with the actin-binding phalloidin rhodamine and DAPI counterstain). 
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Table Legends 
Table 1: Chondrogenic and osteogenic potential of bmMSCs from different donors with varying SSEA-
4 expression levels. Percentages of SSEA-4+ bmMSCs (P3 or 4) were determined by flow cytometry. 
Chondrogenic markers COL2A1 and ACAN, and the amounts of GAG and DNA in pellets were 
quantified by qRT-PCR and biochemical assays, respectively, after 2 weeks of chondrogenic culture. 
The mRNA data from day 14 were normalized to expression levels of undifferentiated bmMSCs of day 
0 and expressed as logarithms. N.D. = not detected. Alkaline phosphatase (ALP) activity in media and 
deposited calcium were also determined after 3 or 4 weeks of osteogenic induction, respectively, and 
normalized to undifferentiated controls.  
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Table 1. 
Donor Gender, 
age 
SSEA-4+ 
cells 
(Overton) 
COL2A1 
(log fold 
change to 
d0) 
ACAN 
(log fold 
change to 
d0) 
GAG 
per DNA 
d14 
ALP assay 
(fold 
difference 
to control) 
Ca2+ assay 
(fold 
difference 
to control) 
#1 male, 22 66.3% 0.9 - 0.6 4.1   
#2 female, 37  17.0% 1.1 - 1.1 4.6   
#3 male, 18 67.5% 5.5   2.3 9.4   
#4 male, 22 65.5% 3.3 - 0.1 4.3 1.6   4.6 
#5 female,75 33.5% 3.4   0.02 
 
3.2 72.7 
#6 female, 32 81.9% N.D. - 0.3 
 
1.1 29.7 
 
 
